Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Eylea

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.

AstraZeneca Patient Profiler TouchTable

EYLEA: Helping see the life beyond the letters - by Bayer HealthCare.

Roche pharma sales strong for first half of 2015

Roche pharma sales strong for first half of 2015 13%, as competition from Regeneron/Bayer's Eylea (aflibercept) and off-label use of Avastin continues to erode sales.

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition For DMO Eylea is given as a 2mg intravitreal injection every month for five months, followed by one injection every two months at a cost of £816 per dose. ... Details of the patient access scheme, which will see Bayer provide a simple discount to

NICE no for new eye disease drug

NICE no for new eye disease drug drugs on the market, including Novartis/Roche's Lucentis (ranibizumab) and Bayer/Regeneron's Eylea (aflibercept).

Roche, Novartis and Bayer gain NICE recommendations

Roche, Novartis and Bayer gain NICE recommendations Bayer has also been granted a recommendation for a new licence for its eye disease drug Eylea (aflibercept). ... In the draft final appraisal determination NICE recommends Eylea for the treatment of patients with diabetic macular oedema (DMO) - a

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics